Givinostat

76 interactions 5 explained in plain English

Also sold as: Duvyzat

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jul 4, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Moxifloxacin Ophthalmic Dolasetron Injection Famotidine Injection Disopyramide Finerenone Oxaliplatin Injection

74 Major 2 Moderate

All (76) Major (74) Moderate (2)

Major

Givinostat Amitriptyline Elavil Explained Increased risk of QT interval prolongation and torsade de pointes Details Givinostat Sertraline Explained Increased risk of QT interval prolongation and torsade de pointes Details Givinostat Buprenorphine Belbuca Explained Increased risk of QT interval prolongation and torsade de pointes Details Givinostat Relugolix Orgovyx Explained Increased risk of QT interval prolongation Details Givinostat Abemaciclib Verzenio Explained Increased CYP3A4 substrate exposure and an increased risk of CYP3A4 substrate-related adverse effects and toxicity Details Givinostat Acalabrutinib Calquence Increased CYP3A4 substrate exposure and an increased risk of CYP3A4 substrate-related adverse effects and toxicity Details Givinostat Amisulpride Injection Barhemsys Increased risk of QT interval prolongation and torsade de pointes Details Givinostat Arsenic Trioxide Trisenox Increased risk of QT interval prolongation and torsade de pointes Details Givinostat Aripiprazole Injection Abilify Increased risk of QT interval prolongation and torsade de pointes Details Givinostat Arsenic Trioxide Injection Trisenox Increased risk of QT interval prolongation and torsade de pointes Details Givinostat Asenapine Transdermal Patch Secuado Increased risk of QT interval prolongation and torsade de pointes Details Givinostat Azithromycin AzaSite Increased risk of QT interval prolongation and torsade de pointes Details Givinostat Alfuzosin UroXatral Increased risk of QT interval prolongation and torsade de pointes Details Givinostat Anagrelide Agrylin Increased risk of QT interval prolongation and torsade de pointes Details Givinostat Bedaquiline Sirturo Increased risk of QT interval prolongation and torsade de pointes Details Givinostat Bosutinib Bosulif Increased CYP3A4 substrate exposure and an increased risk of CYP3A4 substrate-related adverse effects and toxicity Details Givinostat Chloroquine Aralen® Increased risk of QT interval prolongation and torsade de pointes Details Givinostat Cobimetinib Cotellic Increased CYP3A4 substrate exposure and an increased risk of CYP3A4 substrate-related adverse effects and toxicity Details Givinostat Cyclosporine Injection Atopica Increased CYP3A4 substrate exposure and an increased risk of CYP3A4 substrate-related adverse effects and toxicity Details Givinostat Cyclosporine Ophthalmic Cequa Increased CYP3A4 substrate exposure and an increased risk of CYP3A4 substrate-related adverse effects and toxicity Details Givinostat Dasatinib Phyrago Increased CYP3A4 substrate exposure, an increased risk of CYP3A4 substrate-related adverse effects and an increased risk of QT int... Details Givinostat Degarelix Injection Firmagon Increased risk of QT interval prolongation and torsade de pointes Details Givinostat Deutetrabenazine Austedo Increased risk of QT interval prolongation and torsade de pointes Details Givinostat Disopyramide Norpace Increased risk of QT interval prolongation and torsade de pointes Details Givinostat Dofetilide Tikosyn Increased risk of QT interval prolongation and torsade de pointes Details Givinostat Dolasetron Anzemet Increased risk of QT interval prolongation and torsade de pointes Details Givinostat Dolasetron Injection Anzemet Increased risk of QT interval prolongation and torsade de pointes Details Givinostat Encorafenib Braftovi Increased risk of QT interval prolongation and torsade de pointes Details Givinostat Entrectinib Rozlytrek Increased CYP3A4 substrate exposure, an increased risk of CYP3A4 substrate-related adverse effects and an increased risk of QT int... Details Givinostat Eribulin Injection Halaven Increased risk of QT interval prolongation and torsade de pointes Details Givinostat Everolimus Afinitor Increased CYP3A4 substrate exposure and an increased risk of CYP3A4 substrate-related adverse effects and toxicity Details Givinostat Famotidine Calmicid Increased risk of QT interval prolongation and torsade de pointes Details Givinostat Famotidine Injection Calmicid Increased risk of QT interval prolongation and torsade de pointes Details Givinostat Felbamate Felbatol Increased risk of QT interval prolongation and torsade de pointes Details Givinostat Finerenone Kerendia Increased finerenone exposure and an increased risk of finerenone-related adverse effects Details Givinostat Flecainide Tambocor® Increased risk of QT interval prolongation and torsade de pointes Details Givinostat Foscarnet Injection Foscavir Increased risk of QT interval prolongation and torsade de pointes Details Givinostat Galantamine Razadyne Increased risk of QT interval prolongation and torsade de pointes Details Givinostat Gatifloxacin Ophthalmic Zymar® Increased risk of QT interval prolongation and torsade de pointes Details Givinostat Gemifloxacin Factive Increased risk of QT interval prolongation and torsade de pointes Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.